AU3082999A - Combination therapy for treating glaucoma - Google Patents

Combination therapy for treating glaucoma Download PDF

Info

Publication number
AU3082999A
AU3082999A AU30829/99A AU3082999A AU3082999A AU 3082999 A AU3082999 A AU 3082999A AU 30829/99 A AU30829/99 A AU 30829/99A AU 3082999 A AU3082999 A AU 3082999A AU 3082999 A AU3082999 A AU 3082999A
Authority
AU
Australia
Prior art keywords
iop
lowering agent
alkyl
glutamate
glutamate antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30829/99A
Other languages
English (en)
Inventor
Louis DeSantis Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of AU3082999A publication Critical patent/AU3082999A/en
Priority to AU2004214563A priority Critical patent/AU2004214563A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU30829/99A 1999-03-12 1999-03-12 Combination therapy for treating glaucoma Abandoned AU3082999A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004214563A AU2004214563A1 (en) 1999-03-12 2004-09-24 Combination therapy for treating glaucoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/005423 WO2000054810A1 (en) 1999-03-12 1999-03-12 Combination therapy for treating glaucoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004214563A Division AU2004214563A1 (en) 1999-03-12 2004-09-24 Combination therapy for treating glaucoma

Publications (1)

Publication Number Publication Date
AU3082999A true AU3082999A (en) 2000-10-04

Family

ID=22272341

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30829/99A Abandoned AU3082999A (en) 1999-03-12 1999-03-12 Combination therapy for treating glaucoma

Country Status (5)

Country Link
EP (1) EP1169061A1 (de)
AU (1) AU3082999A (de)
CA (1) CA2368242A1 (de)
HK (1) HK1040184A1 (de)
WO (1) WO2000054810A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0200258A2 (hu) 1999-03-05 2002-05-29 The Procter & Gamble Co. C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
CA2574466A1 (en) * 2004-07-22 2006-02-02 Vanda Pharmaceuticals, Inc. Treatment for ocular disease
WO2006015075A1 (en) * 2004-07-26 2006-02-09 Allergan, Inc. Methods of treating ophthalmic conditions
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
MX361709B (es) 2009-11-09 2018-12-07 Allergan Inc Composiciones y metodos para estimular el crecimiento del cabello.
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
SI3431074T1 (sl) 2010-07-29 2022-07-29 Allergan, Inc. Raztopine bimatoprosta in timolola brez konzervansov
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
EP3810082A1 (de) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Wirkstoffabgabesysteme mit verzögerter freisetzung mit einem mittel zur senkung des augeninnendrucks, einer cnp-verbindung, einer npr-b-verbindung, einem tie-2-agonisten oder neurotrophem mittel zur verwendung zur behandlung von glaukom oder okulärer hypertension

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1057486A1 (de) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Verwendung einer Medikamentenkombination zur Behandlung von Glaukom

Also Published As

Publication number Publication date
WO2000054810A1 (en) 2000-09-21
HK1040184A1 (zh) 2002-05-31
CA2368242A1 (en) 2000-09-21
EP1169061A1 (de) 2002-01-09

Similar Documents

Publication Publication Date Title
US6441047B2 (en) Combination therapy for treating glaucoma
AU3082999A (en) Combination therapy for treating glaucoma
US6271224B1 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
US6664286B1 (en) Serotonergic 5ht2 agonists for treating glaucoma
EP1541151A1 (de) MITTEL ZUR BEHANDLUNG VON GLAUKOM MIT EINEM Rho-KINASE-HEMMER UND PROSTAGLANDINEN
AU704938B2 (en) Combination therapy for treating glaucoma
US6486208B1 (en) Sustained release, and comfortable opthalmic composition and method for ocular therapy
EP1568382B1 (de) HEILMITTEL FÜR GRÜNEN STAR, UMFASSEND Rho-KINASE UND beta-BLOCKER
AU715223B2 (en) Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum
EP0672417A1 (de) Verminderung der Innenaugendruck
US6545045B1 (en) Prostaglandin E agonists for treatment of glaucoma
EP1267847B1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
US6200990B1 (en) Neuroprotective agents having antioxidant and NMDA antagonist activity
US5578638A (en) Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
Saxena et al. Pharmacotherapy of glaucoma
EP1647274A1 (de) Mittel zur behandlung von pruritus mit einem piperidin-derivat als wirkstoff
EP3730137B1 (de) Therapeutikum für glaukom mit einem fp-agonisten und timolol
JP4300347B2 (ja) ブナゾシンとプロスタグランジン類からなる緑内障治療剤
AU2004214563A1 (en) Combination therapy for treating glaucoma
AU2001217709B2 (en) Combination therapy for lowering and controlling intraocular pressure
US5308849A (en) Method of reducing elevated intraocular pressure
EP0728480A1 (de) Verwendung von Ifenprodil zur Behandlung von erhöhtem Augeninnendruck
US6927233B1 (en) 5ht2 agonists for controlling IOP and treating glaucoma
AU2001217709A1 (en) Combination therapy for lowering and controlling intraocular pressure
EP0277814B1 (de) Verwendung von Trifluormethansulfonamid gegen Glaukom

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted